Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes: ASCO’s recent policy statement on oncology clinical pathway programs and why value and market access considerations are often missing from clinical trial design.
ASCO Calls for Improvements to Clinical Pathway Programs in Oncology
In a recent policy statement, ASCO detailed specific recommendations “to ensure that clinical pathways in oncology promote—and not hinder—the care of patients with cancer.”
This interview with ASCO Task Force on Clinical Pathways Chair Robin Zon dives into “why ASCO determined it was necessary to make the nine recommendations in the statement and what’s ahead for clinical pathways in oncology.”
This article digs into the process by which clinical trial considerations are chosen and argues that “in the urgency to speed the drug to market, thoroughly integrating value and market access considerations into a product’s clinical program design is often neglected.”
The articles above are from our dedicated Oncology Clinical Pathways e-magazine. Follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)